Here’s What This Multistrategy Money Manager Has Been Buying: Pengrowth Energy Corp (USA) (PGH)

Closed positions of interest include Dendreon Corporation (NASDAQ:DNDN). Most investors in Dendreon, the maker of expensive prostate-cancer drug Provenge, have lost a lot of money. But expectations may now be so low that the company could perform well from here, though it’s also burning through a lot of cash. There’s still value in the company, however, as prostate cancer affects many people. Some analysts have upgraded it, and acceptance in Europe is looking more likely lately. Some are watching to see whether Dendreon will get acquired in the near future.

We should never blindly copy any investor’s moves, no matter how talented the investor. But it can be useful to keep an eye on what smart folks are doing. 13-F forms can be great places to find intriguing candidates for our portfolios.

The article Here’s What This Multistrategy Money Manager Has Been Buying originally appeared on Fool.com and is written by Selena Maranjian.

Longtime Fool contributor Selena Maranjian, whom you can follow on Twitter, has no position in any stocks mentioned. The Motley Fool owns shares of Dendreon.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.